Hope you can join!

Select Phase 1/2 Combination Trials for B-Cell Lymphoma Nathan Fowler MD Anderson Cancer Center Sarah Rutherford Weill Cornell Medicine The James at Ohio State #lymsm ow.ly/kJc750EHc2c

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma ascopubs.org/doi/full/10.12…

Online Now: Conserved pan-cancer microenvironment subtypes predict response to immunotherapy Nathan Fowler BostonGeneCorp dlvr.it/S04HrS

There is no "perfect biomarker" for immunotherapy prediction of response. PD-L1 & TMB are just a reference star in the universe Complexity of tumors needs complex analysis for biomarking. #NGS #transcriptomics is perhaps the answer to next-generation biomarkers 👏Nathan Fowler

.BostonGeneCorp researchers led by Nathan Fowler found the TME subtypes act as a generalized immunotherapy biomarker across many cancer types due to the inclusion of malignant and #microenvironment components. 👉 bit.ly/3bL6Hl4

Our June issue is fresh off the press. Go read it now: cell.com/cancer-cell/is…

Conserved pan-cancer microenvironment subtypes predict response to immunotherapy dlvr.it/S1kVnV

Very cool summary of our recent paper in Cancer Cell. Major impact!

Phenomenal. Congrats Dr Jabbour and team!

Congratulations Nathan Fowler et al on these important data. Love to see a trial vs mosun

See what our experts Drs. Fowler (Nathan Fowler), Nancy L. Bartlett, & Patel (Krish Patel) have to say about targeted, epigenetic, antibody-based, and CAR-T options in the sequential management of #FollicularLymphoma. #ASH21 bit.ly/36nxmlf #meded #lymsm

In an interim analysis of the pivotal phase 2 ELARA trial, anti-CD19 #CARTcells produced a high rate of complete responses with a manageable safety profile in adults with r/r #FollicularLymphoma #lymsm #immunotherapy Nathan Fowler Novartis Cancer nature.com/articles/s4159…

The #FDA has given accelerated approval to #tisagenlecleucel for treatment of adult patients with relapsed or refractory #follicular #lymphoma (#FL). Read about the #ELARA trial, published in Nature Medicine by Nathan Fowler that led to the approval: oncdata.com/news/accelerat…

Very proud of you!!!!

He’s got some truly incredible content but this might be my favorite Dr. Glaucomflecken tweet of all time

Excellente presentation by Ranjit Nair MD Anderson Cancer Center Loretta J. Nastoupil, MD Christopher Flowers showcasing the very promising phase 1 study results of TNB-486 in R/R FL.

thanks everyone for your support. halohousefoundation.org/_api/media-sha…